|
Diabetes Mellitus, Non-Insulin-Dependent
|
0.300 |
Biomarker
|
disease |
BEFREE |
Interestingly, an association between T2D and release of growth hormone (GH) has been reported in humans.
|
31189758 |
2019 |
|
Diabetes Mellitus, Non-Insulin-Dependent
|
0.300 |
Biomarker
|
disease |
BEFREE |
This review discusses the physiological and metabolic actions of GH on adipose tissue as well as GH-mediated deregulation of the FSP27-PPARγ axis which alters adipose tissue homeostasis and contributes to the development of insulin resistance and Type 2 diabetes.
|
31599132 |
2019 |
|
Diabetes Mellitus, Non-Insulin-Dependent
|
0.300 |
Biomarker
|
disease |
BEFREE |
There was no association between LTL and duration of GH treatment, cumulative GH dose or several risk factors for type 2 diabetes mellitus or cardiovascular disease.
|
31689713 |
2019 |
|
Diabetes Mellitus, Non-Insulin-Dependent
|
0.300 |
AlteredExpression
|
disease |
BEFREE |
Abbreviations: AC: adenylyl cyclase; AMPK: AMP-activated protein kinase; βAR: β-adrenergic receptor; CA: catecholamine; cAMP: cyclic adenosine monophosphate; cGMP: cyclic guanosine monophosphate; DPP-4: dipeptidyl peptidase-4; ERK: extracellular signal-regulated kinase; GC: guanylyl cyclase; GH: growth hormone; GLP-1: glucagon-like peptide-1; GLUT: glucose transporter; HSL: hormone-sensitive lipase; IR: insulin receptor; IRS: insulin receptor substrate; MAPK: mitogen-activated protein kinase; MEK: MAPK/ERK kinase; MG: maltase-glucoamylase; NP: natriuretic peptide; NPR: natriuretic peptide receptor; mTORC2: mechanistic target of rapamycin complex-2; PC: proanthocyanidin; PI3K: phosphoinositide 3-kinase; PKA: cAMP-dependent protein kinase; PKB (AKT): protein kinase B; PKG: cGMP-dependent protein kinase; PPARγ: peroxisome proliferator-activated receptor-γ; SGLT1: sodium-dependent glucose transporter 1; SI: sucrase-isomaltase; T2DM: type 2 diabetes mellitus; TNFα: tumor necrosis factor-α.
|
30773997 |
2019 |
|
Diabetes Mellitus, Non-Insulin-Dependent
|
0.300 |
Biomarker
|
disease |
BEFREE |
Some of these indicate the carcinogenic properties of testosterone, dihydrotestosterone (DHT), growth hormone and insulin‑like growth factor (IGF) and others, demonstrating their neutral nature or even their protective one, as in the case of vitamin D. Thus, the synergistic nature of anabolic substances with other CRC risk factors (such as type 2 diabetes mellitus, metabolic syndrome and smoking) has emerged, suggesting a more holistic approach.
|
31578582 |
2019 |
|
Diabetes Mellitus, Non-Insulin-Dependent
|
0.300 |
Biomarker
|
disease |
BEFREE |
The aim of this study was to investigate comorbidities including cerebral infarction, type 2 diabetes mellitus (T2DM) and malignant tumours in patients with non-functioning pituitary adenomas (NFPA) with and without growth hormone replacement therapy (GHRT).
|
30049813 |
2018 |
|
Diabetes Mellitus, Non-Insulin-Dependent
|
0.300 |
Biomarker
|
disease |
BEFREE |
BMI = body mass index; GH = growth hormone; IGF-1 = insulin-like growth factor 1; MRI = magnetic resonance imaging; PSA = prostate-specific antigen; T2DM = type 2 diabetes mellitus; VA-NWIHCS = VA-Nebraska Western Iowa Health Care System.
|
30289304 |
2018 |
|
Diabetes Mellitus, Non-Insulin-Dependent
|
0.300 |
Biomarker
|
disease |
BEFREE |
The aim of this study was to investigate comorbidities including cerebral infarction, type 2 diabetes mellitus (T2DM) and malignant tumors in patients with non-functioning pituitary adenomas (NFPA) with and without growth hormone replacement therapy (GHRT).
|
30299891 |
2018 |
|
Diabetes Mellitus, Non-Insulin-Dependent
|
0.300 |
AlteredExpression
|
disease |
BEFREE |
Patients with type 2 diabetes mellitus have impaired ketogenesis due to high serum insulin and low growth hormone levels.
|
27592119 |
2017 |
|
Diabetes Mellitus, Non-Insulin-Dependent
|
0.300 |
GeneticVariation
|
disease |
BEFREE |
We estimated occurrence of T2DM according to age (10-18 years versus >18 years), body mass index (BMI), genotype, history of growth hormone therapy, homeostasis model of assessment-insulin resistance (HOMA-IR), and the presence of dyslipidemia, hypogonadism, or central precocious puberty.
|
28854950 |
2017 |
|
Diabetes Mellitus, Non-Insulin-Dependent
|
0.300 |
Therapeutic
|
disease |
RGD |
Effects of sericin on the testicular growth hormone/insulin-like growth factor-1 axis in a rat model of type 2 diabetes.
|
26379831 |
2015 |
|
Diabetes Mellitus, Non-Insulin-Dependent
|
0.300 |
GeneticVariation
|
disease |
BEFREE |
Our hypothesis is that genetic variation within the hGH area could predispose to obesity in type 2 diabetes.
|
17211558 |
2006 |
|
Diabetes Mellitus, Non-Insulin-Dependent
|
0.300 |
Biomarker
|
disease |
BEFREE |
Whether the administration of low-dose GH, recombinant IGF-I or combined IGF-I/IGF-binding protein 3 therapy prevents future development of IGT or type 2 diabetes in high-risk normoglycaemic and GH-deficient individuals merits further long-term studies.
|
15761241 |
2004 |
|
Diabetes Mellitus, Non-Insulin-Dependent
|
0.300 |
Biomarker
|
disease |
BEFREE |
These children have poor growth responses to growth hormone (GH) therapy and perhaps the highest type 2 diabetes risk.
|
14671410 |
2003 |
|
Diabetes Mellitus, Non-Insulin-Dependent
|
0.300 |
Biomarker
|
disease |
BEFREE |
The BGLIIA*2/BGLIIB*1 haplotype of GH cluster that was previously found to be negatively associated with severe glucose intolerance in non-insulin-dependent diabetes mellitus (NIDDM) is negatively associated with GH deficit in growth-retarded children.
|
11782864 |
2002 |
|
Diabetes Mellitus, Non-Insulin-Dependent
|
0.300 |
Biomarker
|
disease |
BEFREE |
With the aim of investigating glucose-mediated glucose disposal (glucose effectiveness [GE]) in 15 (3 female and 12 male subjects) insulin-resistant normoglycemic relatives of patients with type 2 diabetes (DM2), and 15 age-, sex-, and BMI-matched control subjects without a family history of DM2, we performed 2 studies: 1) a 5-h euglycemic near-normoinsulinemic pancreatic clamp with somatostatin (360 microg/h), insulin (0.25 mU x kg(-1) x min(-1)), glucagon (0.5 ng x kg(-1) x min(-1)), growth hormone (6 ng x kg(-1) x min(-1)), and tritiated glucose infusion and indirect calorimetry; and 2) on a separate day, an identical 5-h clamp but at hyperglycemia (approximately 12 mmol/l) over the last 2 h. Fasting plasma insulin (PI) concentrations were elevated in the relatives compared with control subjects (49 +/- 6 vs. 32 +/- 5 pmol/l, P < 0.04), whereas plasma glucose (PG) was not (5.6 +/- 0.1 vs. 5.5 +/-0.1 mmol/l).
|
10909980 |
2000 |
|
Diabetes Mellitus, Non-Insulin-Dependent
|
0.300 |
GeneticVariation
|
disease |
BEFREE |
A study of human growth hormone and insulin gene regions in relation to metabolic control of non-insulin-dependent diabetes mellitus.
|
10778862 |
2000 |
|
Diabetes Mellitus, Non-Insulin-Dependent
|
0.300 |
Biomarker
|
disease |
BEFREE |
Symptomatic non-insulin-dependent diabetes mellitus during therapy with recombinant human growth hormone.
|
8093122 |
1993 |
|
Diabetes Mellitus, Non-Insulin-Dependent
|
0.300 |
AlteredExpression
|
disease |
BEFREE |
These abnormalities include low growth hormone levels in response to provocative stimuli, delayed puberty associated with prepubertal levels of gonadotropins in the males and pubertal levels of gonadotropins in the females, type II diabetes mellitus with elevated insulin levels, mild mental retardation, sensori-neural deafness, and alopecia without pili torti.
|
1442893 |
1992 |